195 related articles for article (PubMed ID: 30285874)
1. Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
Chondrou V; Stavrou EF; Markopoulos G; Kouraklis-Symeonidis A; Fotopoulos V; Symeonidis A; Vlachaki E; Chalkia P; Patrinos GP; Papachatzopoulou A; Sgourou A
Hum Genomics; 2018 Oct; 12(1):45. PubMed ID: 30285874
[TBL] [Abstract][Full Text] [Related]
2. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
[No Abstract] [Full Text] [Related]
3. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
Tafrali C; Paizi A; Borg J; Radmilovic M; Bartsakoulia M; Giannopoulou E; Giannakopoulou O; Stojiljkovic-Petrovic M; Zukic B; Poulas K; Stavrou EF; Lambropoulou P; Kourakli A; Felice AE; Papachatzopoulou A; Philipsen S; Pavlovic S; Georgitsi M; Patrinos GP
Pharmacogenomics; 2013 Apr; 14(5):469-83. PubMed ID: 23556445
[TBL] [Abstract][Full Text] [Related]
4. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
5. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
6. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
[TBL] [Abstract][Full Text] [Related]
7. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.
Martyn GE; Wienert B; Yang L; Shah M; Norton LJ; Burdach J; Kurita R; Nakamura Y; Pearson RCM; Funnell APW; Quinlan KGR; Crossley M
Nat Genet; 2018 Apr; 50(4):498-503. PubMed ID: 29610478
[TBL] [Abstract][Full Text] [Related]
8. LRF Promotes Indirectly Advantageous Chromatin Conformation via
Chondrou V; Shaukat AN; Psarias G; Athanasopoulou K; Iliopoulou E; Damanaki A; Stathopoulos C; Sgourou A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806029
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation patterns of β-globin cluster in β-thalassemia patients.
Bao X; Zuo Y; Chen D; Zhao C
Clin Epigenetics; 2020 Dec; 12(1):187. PubMed ID: 33272312
[TBL] [Abstract][Full Text] [Related]
10. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.
Masuda T; Wang X; Maeda M; Canver MC; Sher F; Funnell AP; Fisher C; Suciu M; Martyn GE; Norton LJ; Zhu C; Kurita R; Nakamura Y; Xu J; Higgs DR; Crossley M; Bauer DE; Orkin SH; Kharchenko PV; Maeda T
Science; 2016 Jan; 351(6270):285-9. PubMed ID: 26816381
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness.
Zhu X; Hu T; Ho MH; Wang Y; Yu M; Patel N; Pi W; Choi JH; Xu H; Ganapathy V; Kutlar F; Kutlar A; Tuan D
Haematologica; 2017 Dec; 102(12):1995-2004. PubMed ID: 28971909
[TBL] [Abstract][Full Text] [Related]
12. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Insights and Potential Modifiers as Therapeutic Targets in
Zakaria NA; Islam MA; Abdullah WZ; Bahar R; Mohamed Yusoff AA; Abdul Wahab R; Shamsuddin S; Johan MF
Biomolecules; 2021 May; 11(5):. PubMed ID: 34070036
[TBL] [Abstract][Full Text] [Related]
14. Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype.
Ngo D; Bae H; Steinberg MH; Sebastiani P; Solovieff N; Baldwin CT; Melista E; Safaya S; Farrer LA; Al-Suliman AM; Albuali WH; Al Bagshi MH; Naserullah Z; Akinsheye I; Gallagher P; Luo HY; Chui DH; Farrell JJ; Al-Ali AK; Alsultan A
Blood Cells Mol Dis; 2013 Jun; 51(1):22-6. PubMed ID: 23465615
[TBL] [Abstract][Full Text] [Related]
15. Variants of ZBTB7A (LRF) and its β-globin gene cluster binding motifs in sickle cell anemia.
Shaikho EM; Habara AH; Alsultan A; Al-Rubaish AM; Al-Muhanna F; Naserullah Z; Alsuliman A; Qutub HO; Patra PK; Sebastiani P; Baltrusaitis K; Farrell JJ; Jiang Z; Luo HY; Chui DH; Al-Ali AK; Steinberg MH
Blood Cells Mol Dis; 2016 Jul; 59():49-51. PubMed ID: 27282567
[No Abstract] [Full Text] [Related]
16. Structural basis for human ZBTB7A action at the fetal globin promoter.
Yang Y; Ren R; Ly LC; Horton JR; Li F; Quinlan KGR; Crossley M; Shi Y; Cheng X
Cell Rep; 2021 Sep; 36(13):109759. PubMed ID: 34592153
[TBL] [Abstract][Full Text] [Related]
17. KLF1 directly activates expression of the novel fetal globin repressor
Norton LJ; Funnell APW; Burdach J; Wienert B; Kurita R; Nakamura Y; Philipsen S; Pearson RCM; Quinlan KGR; Crossley M
Blood Adv; 2017 Apr; 1(11):685-692. PubMed ID: 29296711
[TBL] [Abstract][Full Text] [Related]
18. Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea.
Hojjati MT; Azarkeivan A; Pourfathollah AA; Amirizadeh N
Hemoglobin; 2017 Mar; 41(2):110-115. PubMed ID: 28696844
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
20. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
Bauer DE; Orkin SH
Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
